tiprankstipranks
1st Group Ltd. (AU:VFX)
ASX:VFX
Australian Market

1st Group Ltd. (VFX) AI Stock Analysis

Compare
3 Followers

Top Page

AU:VFX

1st Group Ltd.

(Sydney:VFX)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 5.2)
Rating:43Neutral
Price Target:
AU$0.08
▼(-25.00% Downside)
Action:ReiteratedDate:03/05/26
The score is weighed down primarily by weak financial performance (losses, negative equity, and continued cash burn). Technicals also point to a weak trend with negative momentum. Valuation offers limited support because the negative P/E reflects losses and there is no dividend yield data.
Positive Factors
Industry Positioning
Operating in Medical - Healthcare Information Services places the company in a structurally growing sector driven by long-term demand for clinical information and analytics. This market orientation supports recurring demand and potential for product-led scale over multiple years.
Negative Factors
Negative Shareholder Equity
Persistent negative shareholder equity constrains financial flexibility, limits access to traditional financing, and increases dilution risk if capital is needed. Over months, this structural capital deficit raises the probability of external funding or restructuring to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Industry Positioning
Operating in Medical - Healthcare Information Services places the company in a structurally growing sector driven by long-term demand for clinical information and analytics. This market orientation supports recurring demand and potential for product-led scale over multiple years.
Read all positive factors

1st Group Ltd. (VFX) vs. iShares MSCI Australia ETF (EWA)

1st Group Ltd. Business Overview & Revenue Model

Company Description
Visionflex Group Limited, together its subsidiaries, engages in the provision of healthcare, telehealth, and remote diagnostic solutions in Australia. The company offers virtual healthcare solutions and peripheral medical devices that integrate in...
How the Company Makes Money
null...

1st Group Ltd. Financial Statement Overview

Summary
Financial health is high-risk: profitability is weak and worsening (deep operating/net losses and negative gross profit in 2025), shareholder equity is negative across periods (limited flexibility), and cash flow remains negative (ongoing cash burn). Debt improved in 2025 and free cash flow improved year-over-year, but the business is still not self-funding.
Income Statement
14
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
BreakdownJun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue4.19M6.65M4.47M4.83M
Gross Profit-2.42M3.94M3.41M4.83M
EBITDA-3.37M-1.32M-3.56M-6.43M
Net Income-3.19M-1.83M-3.66M-6.82M
Balance Sheet
Total Assets3.39M2.88M4.09M4.27M
Cash, Cash Equivalents and Short-Term Investments1.89M1.16M1.44M2.01M
Total Debt2.47M13.65M12.11M4.65M
Total Liabilities5.22M19.76M18.73M8.16M
Stockholders Equity-1.82M-8.11M-6.74M-3.89M
Cash Flow
Free Cash Flow-3.19M-1.38M-3.68M-2.82M
Operating Cash Flow-3.16M0.000.000.00
Investing Cash Flow-29.51K276.80K720.13K-21.84K
Financing Cash Flow3.92M798.81K2.36M4.59M

1st Group Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
AU$13.12M-1.00-218.76%
43
Neutral
AU$6.75M-1.11245.46%
41
Neutral
AU$4.12M-1.9820.02%-9.90%34.07%
41
Neutral
AU$6.99M-1.62-44.35%-18.70%20.83%
41
Neutral
AU$7.59M-0.96152.58%-40.05%-49.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:VFX
1st Group Ltd.
0.08
<0.01
2.63%
AU:GLH
Global Health Limited
0.07
-0.04
-39.09%
AU:EVE
EVE Health Group Limited
0.02
>-0.01
-33.33%
AU:CMB
Regeneus Ltd.
0.48
0.13
37.14%
AU:HIQ
HitIQ Limited
0.01
-0.02
-67.57%

1st Group Ltd. Corporate Events

Visionflex lifts recurring revenue as it shifts to subscription-led telehealth model
Feb 26, 2026
Visionflex reported H1 FY26 revenue of $1.7 million, down 10% on the prior period, but lifted recurring revenue by 29% to $0.9 million, with subscriptions and support now contributing about 52% of total revenue. Annual recurring revenue rose 23% t...
Visionflex Group Releases FY26 Interim Financial Report
Feb 26, 2026
Visionflex Group Limited has released its FY26 Appendix 4D and interim financial report, outlining the company&#8217;s consolidated financial statements and directors&#8217; commentary for the period. The report package includes profit and loss, b...
Visionflex Seeks ASX Quotation for Additional Ordinary Shares
Feb 3, 2026
Visionflex Group Limited has applied to the ASX for quotation of 36,110 new fully paid ordinary shares under its existing issuer code VFX. The additional securities arise from the exercise or conversion of existing options or other convertible sec...
Visionflex Options Lapse, Removing Potential Future Dilution
Jan 30, 2026
Visionflex Group Limited has announced the expiry of 9,736,607 unexercised options, each with an exercise price of A$0.35 and an expiry date of 25 January 2026, resulting in the cessation of these securities from its issued capital. The lapse of t...
Visionflex Posts Modest Quarterly Cash Outflow but Maintains Solid Cash Buffer
Jan 22, 2026
Visionflex Group Limited reported a modest cash outflow from operations for the quarter ended 31 December 2025, with net operating cash used of A$290,000 on customer receipts of A$982,000, partly offset by A$569,000 in government grants and tax in...
Visionflex lifts recurring revenue and tightens costs as aged care and RFDS deals advance
Jan 22, 2026
Visionflex Group reported mixed Q2 FY26 results, with customer cash receipts rising 22% year-on-year to $1 million and operating cash outflows improving to $0.3 million, supported by tighter cost control and a growing base of higher-margin recurri...
Visionflex Options Lapse Following Expiry Without Exercise
Jan 4, 2026
Visionflex Group Limited has notified the market that 553,395 options with an exercise price of $0.35, expiring on 2 January 2026, have lapsed unexercised. The cessation of these options slightly reduces the company&#8217;s pool of potential equit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 05, 2026